Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264797 | 0.91 | KMT2A (0.58) | KDM4EALDH1A1LMNANPSR1GAA | |
| SCHEMBL13183878 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1LMNANPSR1GAA | |
| Potassium Ion SCHEMBL10575064 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1LMNANPSR1GAA | |
| SCHEMBL29755360 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1LMNANPSR1GAA | |
| SCHEMBL15851432 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1LMNANPSR1GAA | |
| Potassium SCHEMBL10575068 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1LMNANPSR1GAA | |
| SCHEMBL9780205 | 0.81 | KMT2A (0.49) | KDM4EALDH1A1LMNANPSR1GAA | |
| Fluorene SCHEMBL4327570 | 0.80 | MAOA (0.65) | KDM4EALDH1A1LMNANPSR1GAA | |
| SCHEMBL18184514 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1LMNANPSR1GAA | |
| SCHEMBL20364684 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1LMNANPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110658163-A | Method for monitoring reaction in synthesis of DNA coding compound | 成都先导药物开发股份有限公司 | 2020-01-07 | — | — | CN | claimed |
| CN-110658163-A | Method for monitoring reaction in synthesis of DNA coding compound | 成都先导药物开发股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-1233017-B1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6906092-B2 | Method of inhibiting matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6620835-B2 | Sulfonamide-substituted benzothiophenes (that may be oxidized), carbazoles, fluorenes and fluorenones | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2003-02-13 | — | — | US | disclosed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6294674-B1 | FOR THERAPY OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, RESTENOSIS, AORTIC ANEURISM, HEART FAILURE, PERIODONTAL DISEASE, CORNEAL ULCERATION, BURNS, DECUBITAL ULCERS, CHRONIC ULCERS OR WOUNDS, CANCER METASTASIS | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| US-4857644-A | Aryl sulfonopiperazines as anti-inflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | KDM4E 3386/4885ALDH1A1 387/4885LMNA 4322/4885 |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | KDM4E 3386/4885ALDH1A1 387/4885LMNA 4322/4885 |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | MMP9, MMP10, MMP3 | KDM4E 1309/4885ALDH1A1 1386/4885LMNA 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.